No method currently exists to gauge the aggressiveness of prostate cancer, putting the patient and his doctors into a quandary about the proper treatment strategy. Should they be aggressive or just watchfully wait?
Now a study from the University of Pittsburgh School of Medicine has identified eight gene mutations known as gene fusions that signal aggressive forms of prostate cancer, raising hope of better treatment strategies and new targets for treatments.
The study focused on 289 prostate samples. Of 76 patient samples found to contain one or more of eight gene fusions, 69 patients’ prostrate cancer recurred, metastasized or led to death. The mere existence of the fusions were 91 percent successful in predicting cancer recurrence, compared with 37 percent of cancer recurrence in men showing none of the fusions.
The study also showed that samples containing even one of three specific fusions had a 100 percent chance of cancer recurrence.
“Being able to say, with such certainty, that a patient is nearly guaranteed to see a recurrence of his prostate cancer means that doctors and patients can elect to be more aggressive in treating the cancer, knowing that the benefits likely outweigh the risk,” said Jian-Hua Luo, who joined PItt/UPMC doctors Joel B. Nelson and George Michalopoulos as principal investigators in the study.
More aggressive treatment can include removal of the prostate (prostatectomy), radiation and/or hormone therapy, among others, as opposed to watchful waiting to monitor the cancer’s progress.
The Pitt study, published Monday in the American Journal of Pathology, announced the discovery of the eight gene fusions. Dr. Luo expressed hope that the RNA-sequencing technique the team used could become available for use as soon as the research is validated.
Gene fusions, he said, can occur from various factors including epigenetic ones such as exposure to radiation or other environmental risks that damage genes. The result can be a sometimes errant repair process that produces jumbled, abnormal chromosomes that can include sequence breaks and misplaced DNA sequences with unrelated chromosomes becoming conjoined. The result are genes with the “wrong pieces and wrong DNA,” Dr. Luo said.
The Pitt team sequenced all RNA in the human genome 1,333 times to discover the eight gene fusions. They also sequenced the entire genome 30 times. The three key fusions were shown to block development of proteins that suppress tumor growth.
The Pitt test would not serve as an initial test, such as the prostate-specific antigen test, or PSA, to indicate whether or not a man has a higher risk of prostate cancer. Instead, it would be used to test tissue in prostate biopsies that are positive for cancer in order to predict aggressiveness.
The team already has begun research on the newly discovered gene fusions as targets for potential treatments.
Jerry Bortman, secretary and health director for the Obediah Cole Foundation for Prostate Cancer in Peters, which provides education and prostate-testing services for men lacking insurance, said the Pitt research represents long-awaited good news.
“The holy grail is to catch the more aggressive ones and treat them right away and do more watchful waiting for the other ones,” he said, adding that current testing cannot gauge the aggressiveness of prostate cancers.
A new Prostate Health Index (PHI) is being investigated as an improved method to detect prostate cancer by analyzing various aspects of PSA results, with some added information about aggressiveness. There is hope, he said, that more accurate methods to test men for prostate cancer are on the horizon.
“Two weeks ago, I was interested in the PHI test, but [the Pitt test] might be better,” Mr. Bortman said.
“





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.